Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials

Table 1 The important characteristics of controlled trials of quetiapine in major depressive disorder

Study (author, year)	Number of patients	Age of subjects (years)	Study duration (weeks)	Drug /Dose	Diagnostic criteria	Respond criteria	Remission criteria	Outcome measures
Cutler AJ 2009	461	18–65	8	Quetiapine XR/150 and 300 mg/day	DSM IV	≥ 50% reduction in MADRS	MADRS ≤ 8	MADRS, HAM-D, HAM-A, CGI-S, CGI-I, PSQI, SAS, BARS, CSFQ, 18-item TDSS scale
Weisler R 2009	700	18–65	8	Quetiapine XR/50, 150 and 300 mg/day	DSM IV	≥ 50% reduction in MADRS	MADRS ≤ 8	MADRS, HAM-D, HAM-A, CGI-S, CGI-I, PSQI, SAS, BARS, CSFQ, Q-LES-Q, 18-item TDSS scale
Bortnick B 2011	299	18–65	10	Quetiapine XR/150 to 300 mg/day	DSM IV	≥ 50% reduction in MADRS	MADRS ≤ 8	MADRS, HAM-D, HAM-A, CGI-S, CGI-I, PSQI, SAS, BARS, CSFQ, Q-LES-Q, 18-item TDSS scale

MADRS = Montgomery-Åsberg Depression Rating Scale; HAM-D = Hamilton Rating Scale for Depression; HAM-A = Hamilton Rating Scale for Anxiety; CGI-S= Clinical Global Impression–Severity of Illness; CGI-I = Clinical Global Impression–Improvement scale; PSQI = Pittsburgh Sleep Quality Index; SAS = Simpson-Angus Scale, BARS = Barnes Akathisia Rating Scale; CSFQ = Changes in Sexual Functioning Questionnaire; Q-LES-Q = Quality of Life Enjoyment Satisfaction Questionnaire; TDSS scale = Treatment discontinuation.

ISSN: 1471-244X